Q2 EPS Estimates for Gossamer Bio Increased by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of Gossamer Bio in a research note issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.15) per share for the quarter, up from their prior forecast of ($0.17). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio's Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.17) EPS.

Several other research analysts also recently weighed in on GOSS. The Goldman Sachs Group upped their target price on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, May 16th. Wedbush reaffirmed an "outperform" rating and issued a $4.00 target price on shares of Gossamer Bio in a report on Friday, May 16th.

Gossamer Bio Stock Performance

Shares of GOSS stock traded up $0.04 during mid-day trading on Monday, reaching $1.16. 832,127 shares of the company's stock traded hands, compared to its average volume of 1,546,020. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55. The firm has a 50 day moving average price of $1.01 and a two-hundred day moving average price of $1.00. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market capitalization of $263.67 million, a PE ratio of -3.63 and a beta of 1.82.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of GOSS. Octagon Capital Advisors LP boosted its holdings in Gossamer Bio by 99.7% in the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company's stock worth $16,599,000 after buying an additional 9,162,117 shares during the period. Alyeska Investment Group L.P. lifted its stake in Gossamer Bio by 52.7% in the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company's stock worth $7,968,000 after purchasing an additional 3,041,058 shares in the last quarter. Monaco Asset Management SAM lifted its stake in Gossamer Bio by 39.5% in the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock worth $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Gossamer Bio by 24.6% in the 1st quarter. Acadian Asset Management LLC now owns 6,358,113 shares of the company's stock worth $6,991,000 after purchasing an additional 1,253,353 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Gossamer Bio by 720.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company's stock worth $1,034,000 after purchasing an additional 825,047 shares in the last quarter. Institutional investors own 81.23% of the company's stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.